Etanercept

An evolving role in psoriasis and psoriatic arthritis

Srdjan Prodanovich, Carlos Ricotti, Brad P. Glick, Luca A Inverardi, Craig L. Leonardi, Francisco Kerdel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalAmerican Journal of Clinical Dermatology
Volume11
Issue numberSUPPL. 1
DOIs
StatePublished - Jul 9 2010
Externally publishedYes

Fingerprint

Psoriatic Arthritis
Psoriasis
Disease Management
Arthritis
Disease Progression
Tumor Necrosis Factor-alpha
Economics
Etanercept
Clinical Trials

ASJC Scopus subject areas

  • Dermatology

Cite this

Prodanovich, S., Ricotti, C., Glick, B. P., Inverardi, L. A., Leonardi, C. L., & Kerdel, F. (2010). Etanercept: An evolving role in psoriasis and psoriatic arthritis. American Journal of Clinical Dermatology, 11(SUPPL. 1), 3-9. https://doi.org/10.2165/1153413-S0-000000000-00000

Etanercept : An evolving role in psoriasis and psoriatic arthritis. / Prodanovich, Srdjan; Ricotti, Carlos; Glick, Brad P.; Inverardi, Luca A; Leonardi, Craig L.; Kerdel, Francisco.

In: American Journal of Clinical Dermatology, Vol. 11, No. SUPPL. 1, 09.07.2010, p. 3-9.

Research output: Contribution to journalArticle

Prodanovich, S, Ricotti, C, Glick, BP, Inverardi, LA, Leonardi, CL & Kerdel, F 2010, 'Etanercept: An evolving role in psoriasis and psoriatic arthritis', American Journal of Clinical Dermatology, vol. 11, no. SUPPL. 1, pp. 3-9. https://doi.org/10.2165/1153413-S0-000000000-00000
Prodanovich S, Ricotti C, Glick BP, Inverardi LA, Leonardi CL, Kerdel F. Etanercept: An evolving role in psoriasis and psoriatic arthritis. American Journal of Clinical Dermatology. 2010 Jul 9;11(SUPPL. 1):3-9. https://doi.org/10.2165/1153413-S0-000000000-00000
Prodanovich, Srdjan ; Ricotti, Carlos ; Glick, Brad P. ; Inverardi, Luca A ; Leonardi, Craig L. ; Kerdel, Francisco. / Etanercept : An evolving role in psoriasis and psoriatic arthritis. In: American Journal of Clinical Dermatology. 2010 ; Vol. 11, No. SUPPL. 1. pp. 3-9.
@article{c87d02df9efa4e0892f26a2de716b5e9,
title = "Etanercept: An evolving role in psoriasis and psoriatic arthritis",
abstract = "Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.",
author = "Srdjan Prodanovich and Carlos Ricotti and Glick, {Brad P.} and Inverardi, {Luca A} and Leonardi, {Craig L.} and Francisco Kerdel",
year = "2010",
month = "7",
day = "9",
doi = "10.2165/1153413-S0-000000000-00000",
language = "English",
volume = "11",
pages = "3--9",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Etanercept

T2 - An evolving role in psoriasis and psoriatic arthritis

AU - Prodanovich, Srdjan

AU - Ricotti, Carlos

AU - Glick, Brad P.

AU - Inverardi, Luca A

AU - Leonardi, Craig L.

AU - Kerdel, Francisco

PY - 2010/7/9

Y1 - 2010/7/9

N2 - Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.

AB - Tumor necrosis factor alpha (TNFα) plays a key pathophysiological role in psoriasis and psoriatic arthritis (PsA). Recent interest has thus focused on the clinical potential of TNFa antagonists (e.g. etanercept) in these settings. In psoriasis, several large pooled analyses and well-designed clinical trials documented the significant clinical efficacy and generally favorable tolerability of etanercept for up to 96 weeks. Similarly, in PsA, a large phase III trial showed that, etanercept significantly reduced arthritic symptoms and inhibited radiographic disease progression; sustained clinical benefit was again evident for up to 2 years. Etanercept is at the forefront of psoriatic disease management, and continued evolution and evaluation of the compound - for example, in detailed comparative studies and economic analyses - is likely to confirm a key role for etanercept in the treatment of psoriasis and PsA.

UR - http://www.scopus.com/inward/record.url?scp=77954276700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954276700&partnerID=8YFLogxK

U2 - 10.2165/1153413-S0-000000000-00000

DO - 10.2165/1153413-S0-000000000-00000

M3 - Article

VL - 11

SP - 3

EP - 9

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - SUPPL. 1

ER -